Pediatric growth hormone deficiency occurs when the pituitary gland fails to produce an adequate amount of growth hormone, hindering the growth of bones and other tissues. The standard treatment for growth hormone deficiency is daily injections of recombinant human growth hormone (rHGH).
The stock we are bringing to your attention today is that of Lumos Pharma Inc. (LUMO), a clinical stage biopharmaceutical company, developing a once-daily tablet for pediatric growth hormone deficiency.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com